The Italian Autorità Garante della Concorrenza e del Mercato (“AGCM”) has fined Aspen over €5 million for having abused its dominant position – in violation of Art. 102 of the Treaty on the Functioning of the European Union – by increasing prices of its anti-cancer drugs Alkeran (melphalan), Leukeran (chlorambucil), Purinethol (mercaptopurine) and Tioguanine (thioguanine)
Italian Competition Authority
The Italian Competition Authority launches a sector inquiry in relation to vaccines for human use
By Inside EU Life Sciences on
Posted in Competition, Pharmaceutical companies
On 27 May 2015, the Italian Competition Authority (ICA) issued a decision launching a sector inquiry into the supply of vaccines for human use.
The ICA has stated that it has launched the sector inquiry because of:
- the importance of vaccines in terms of health care costs borne by the Italian National Health Service (over
…